Cargando…
Therapeutic Potential of Targeting ß-Arrestin
ß-arrestins are multifunctional proteins that modulate heptahelical 7 transmembrane receptors, also known as G protein-coupled receptors (GPCRs), a superfamily of receptors that regulate most physiological processes. ß-arrestin modulation of GPCR function includes termination of G protein-dependent...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414794/ https://www.ncbi.nlm.nih.gov/pubmed/30894814 http://dx.doi.org/10.3389/fphar.2019.00124 |
_version_ | 1783403042086846464 |
---|---|
author | Bond, Richard A. Lucero Garcia-Rojas, Emilio Y. Hegde, Akhil Walker, Julia K. L. |
author_facet | Bond, Richard A. Lucero Garcia-Rojas, Emilio Y. Hegde, Akhil Walker, Julia K. L. |
author_sort | Bond, Richard A. |
collection | PubMed |
description | ß-arrestins are multifunctional proteins that modulate heptahelical 7 transmembrane receptors, also known as G protein-coupled receptors (GPCRs), a superfamily of receptors that regulate most physiological processes. ß-arrestin modulation of GPCR function includes termination of G protein-dependent signaling, initiation of ß-arrestin-dependent signaling, receptor trafficking to degradative or recycling pathways, receptor transactivation, transcriptional regulation, and localization of second messenger regulators. The pleiotropic influence ß-arrestins exert on these receptors regulates a breadth of physiological functions, and additionally, ß-arrestins are involved in the pathophysiology of numerous and wide-ranging diseases, making them prime therapeutic targets. In this review, we briefly describe the mechanisms by which ß-arrestins regulate GPCR signaling, including the functional cellular mechanisms modulated by ß-arrestins and relate this to observed pathophysiological responses associated with ß-arrestins. We focus on the role for ß-arrestins in transducing cell signaling; a pathway that is complementary to the classical G protein-coupling pathway. The existence of these GPCR dual signaling pathways offers an immense therapeutic opportunity through selective targeting of one signaling pathway over the other. Finally, we will consider several mechanisms by which the potential of dual signaling pathway regulation can be harnessed and the implications for improved disease treatments. |
format | Online Article Text |
id | pubmed-6414794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64147942019-03-20 Therapeutic Potential of Targeting ß-Arrestin Bond, Richard A. Lucero Garcia-Rojas, Emilio Y. Hegde, Akhil Walker, Julia K. L. Front Pharmacol Pharmacology ß-arrestins are multifunctional proteins that modulate heptahelical 7 transmembrane receptors, also known as G protein-coupled receptors (GPCRs), a superfamily of receptors that regulate most physiological processes. ß-arrestin modulation of GPCR function includes termination of G protein-dependent signaling, initiation of ß-arrestin-dependent signaling, receptor trafficking to degradative or recycling pathways, receptor transactivation, transcriptional regulation, and localization of second messenger regulators. The pleiotropic influence ß-arrestins exert on these receptors regulates a breadth of physiological functions, and additionally, ß-arrestins are involved in the pathophysiology of numerous and wide-ranging diseases, making them prime therapeutic targets. In this review, we briefly describe the mechanisms by which ß-arrestins regulate GPCR signaling, including the functional cellular mechanisms modulated by ß-arrestins and relate this to observed pathophysiological responses associated with ß-arrestins. We focus on the role for ß-arrestins in transducing cell signaling; a pathway that is complementary to the classical G protein-coupling pathway. The existence of these GPCR dual signaling pathways offers an immense therapeutic opportunity through selective targeting of one signaling pathway over the other. Finally, we will consider several mechanisms by which the potential of dual signaling pathway regulation can be harnessed and the implications for improved disease treatments. Frontiers Media S.A. 2019-03-06 /pmc/articles/PMC6414794/ /pubmed/30894814 http://dx.doi.org/10.3389/fphar.2019.00124 Text en Copyright © 2019 Bond, Lucero Garcia-Rojas, Hegde and Walker. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Bond, Richard A. Lucero Garcia-Rojas, Emilio Y. Hegde, Akhil Walker, Julia K. L. Therapeutic Potential of Targeting ß-Arrestin |
title | Therapeutic Potential of Targeting ß-Arrestin |
title_full | Therapeutic Potential of Targeting ß-Arrestin |
title_fullStr | Therapeutic Potential of Targeting ß-Arrestin |
title_full_unstemmed | Therapeutic Potential of Targeting ß-Arrestin |
title_short | Therapeutic Potential of Targeting ß-Arrestin |
title_sort | therapeutic potential of targeting ß-arrestin |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414794/ https://www.ncbi.nlm.nih.gov/pubmed/30894814 http://dx.doi.org/10.3389/fphar.2019.00124 |
work_keys_str_mv | AT bondricharda therapeuticpotentialoftargetingßarrestin AT lucerogarciarojasemilioy therapeuticpotentialoftargetingßarrestin AT hegdeakhil therapeuticpotentialoftargetingßarrestin AT walkerjuliakl therapeuticpotentialoftargetingßarrestin |